TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18992161

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Number of subjects: 535

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Visual acuity change (continuous)
Number of subjects: 535
Study: 12775860

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 250 micro g administered twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10684846

Group type: EXPERIMENTAL
Intervention: Spectacles
Number of subjects: 289

Group type: COMPARATOR
Intervention: No treatment (Control group: children with strabismus)
Number of subjects: 289
Study: 9085945

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg bolus followed by an infusion of 5 mg/h for 24 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8448098

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% injected at L2-3 interspace
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% injected at L4-5 interspace
Number of subjects: 20
Study: 3536377

Group type: COMPARATOR
Intervention: 50 mg methadone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 60 mg methadone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 75 mg methadone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100 mg methadone
Number of subjects: 5
Study: 29107078

Group type: EXPERIMENTAL
Intervention: Medical-grade honey (MGH)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Mupirocin 2%
Number of subjects: 86
Study: 29231565

Group type: EXPERIMENTAL
Intervention: Acupoint injection of human placenta tissue fluid combined with oral administration of metformin hydrochloride enteric-coated tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of metformin hydrochloride enteric-coated tablets
Number of subjects: 60
Study: 24503176

Group type: EXPERIMENTAL
Intervention: Minocycline (200mg per day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 22615527

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oxitropium 0.2 mg x 3 mg
Number of subjects: 17
Study: 20636724

Group type: EXPERIMENTAL
Intervention: Straumann Bone Ceramic (SBC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bio-Oss deproteinized bovine bone mineral (DBBM)
Number of subjects: 27
Study: 18227298

Group type: EXPERIMENTAL
Intervention: 15-minute presurgery hypnosis session
Number of subjects: 90

Group type: COMPARATOR
Intervention: 15-minute presurgery attention control session
Number of subjects: 90
Study: 15830958

Group type: EXPERIMENTAL
Intervention: Surgery for TOS
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Surgery for TOS (in second group)
Number of subjects: 280
Study: 12606909

Group type: EXPERIMENTAL
Intervention: Fast-track cardiac anesthesia (FTCA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional anesthetic
Number of subjects: 120
Study: 10354167

Group type: EXPERIMENTAL
Intervention: ALA‐PDT with white light applied three times within 10 days (W3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ALA‐PDT with white light applied once (W1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ALA‐PDT with red light applied three times within 10 days (R3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ALA‐PDT with blue light applied three times within 10 days (B3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cryotherapy applied up to four times within 2 months (CRYO)
Number of subjects: 30
Study: 10999066

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg i.v. prior to chemotherapy followed by two further doses of 8 mg i.v. over the first 24 hours, then 8 mg b.d. orally for the next 5 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Metoclopramide 20 mg i.v. prior to chemotherapy followed by 2 i.v. doses of 10 mg each, 4 hours apart, then 20 mg orally for the next 5 days
Number of subjects: 93
Study: 1649672

Group type: EXPERIMENTAL
Intervention: Human insulin (NOVO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Monocomponent porcine insulin
Number of subjects: 16
Study: 6871053

Group type: EXPERIMENTAL
Intervention: Fentanyl plus i.v. anaesthesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spinal plus i.v. anaesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: i.v. anaesthesia alone
Number of subjects: 45
Study: 30292891

Group type: EXPERIMENTAL
Intervention: Adjunctive urine LAM testing (n=1257)
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: Routine diagnostics plus adjunctive urine LAM testing (n=1257)
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: Higher LAM grade (grades 4 and 5)
Number of subjects: 2528

Group type: COMPARATOR
Intervention: Routine diagnostics (n=1271)
Number of subjects: 2528
Study: 27022961

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 119
Study: 27287454

Group type: EXPERIMENTAL
Intervention: Sedation during DMSA scan
Number of subjects: 798

Group type: COMPARATOR
Intervention: Non-sedation during DMSA scan
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Selective sedation during DMSA scan
Number of subjects: 798
Study: 25390874

Group type: EXPERIMENTAL
Intervention: Zirconia (ZrO₂) abutments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Titanium (Ti) abutments
Number of subjects: 20
Study: 22392358

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional laparoscopic adrenalectomy
Number of subjects: 40
Study: 19224163

Group type: EXPERIMENTAL
Intervention: Anluohuaxian tablet + gamma-IFN
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anluohuaxian tablet
Number of subjects: 60

Group type: COMPARATOR
Intervention: gamma-IFN
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined treatment (anluohuaxian tablet + gamma-IFN)
Number of subjects: 60
Study: 17966930

Group type: EXPERIMENTAL
Intervention: Conventional cytopathology of oral brush biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA image cytometry as an adjuvant diagnostic tool
Number of subjects: 0
Study: 14687313

Group type: EXPERIMENTAL
Intervention: Educational materials mailed to intervention practice households; waiting and examination room posters provided to intervention office practices.
Number of subjects: 4270

Group type: COMPARATOR
Intervention: Control practices (51 practices) without the educational intervention.
Number of subjects: 4270
Study: 11726432

Group type: EXPERIMENTAL
Intervention: Oral vitamin B complex (folate 2.5 mg, B(6) 25 mg, and B(12) 500 microg) daily for 1 week before surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 9656906

Group type: EXPERIMENTAL
Intervention: Procaine + simulated dry needling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dry needling + simulated local anesthetic
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simulated local anesthetic + simulated dry needling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 30
Study: 8485020

Group type: EXPERIMENTAL
Intervention: 15 mg MTX i.v.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg MTX i.m.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg MTX p.o.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg MTX (all routes)
Number of subjects: 9
Study: 3318348

Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg/day for 7 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31273290

Group type: EXPERIMENTAL
Intervention: ADT + D (Docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADT + AA (Abiraterone Acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose AA (250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADT + AA
Number of subjects: 0
Study: 30264056

Group type: EXPERIMENTAL
Intervention: Topical application of amino acid and sodium hyaluronate gel
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sterile saline solution (Control)
Number of subjects: 136
Study: 27003242

Group type: EXPERIMENTAL
Intervention: Tai Chi training (12-form Yang style Tai Chi)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (general interest classes)
Number of subjects: 31
Study: 26866082

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 20 mcg 2-hourly up to a maximum of 4 doses
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intravenous oxytocin according to WHO protocol
Number of subjects: 83
Study: 22248659

Group type: EXPERIMENTAL
Intervention: Mericitabine (500 or 1000 mg, twice daily) plus danoprevir (100 or 200 mg, every 8 hours, or 600 or 900 mg, twice daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 19744259

Group type: COMPARATOR
Intervention: Intralesional sodium stibogluconate (SSG) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intralesional SSG + intramuscular SSG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intralesional SSG + oral ketoconazole
Number of subjects: 30
Study: 18503923

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - single 5‐minute ischemia/reperfusion interval before coronary occlusion (n = 9)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia - 1.6% enflurane 15 minutes before and during graft attachment (n = 8)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 25
Study: 15713352

Group type: EXPERIMENTAL
Intervention: Voglibose (0.4-0.6 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no voglibose)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 101
Study: 12815682

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 12798444

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg slow release matrix tablet, acute application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin (2-month medication regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin (after nanoplaque generation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HDL (as a comparison)
Number of subjects: 0
Study: 9583763

Group type: EXPERIMENTAL
Intervention: Supervised fitness programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 7634730

Group type: EXPERIMENTAL
Intervention: Cortisone injection with lidocaine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cortisone injection with bupivacaine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cortisone injection (regardless of anesthetic)
Number of subjects: 109
Study: 2677289

Group type: EXPERIMENTAL
Intervention: Vialon I.V. catheters
Number of subjects: 191

Group type: COMPARATOR
Intervention: Teflon I.V. catheters
Number of subjects: 191
Study: 411398

Group type: EXPERIMENTAL
Intervention: Aerosolized atropine sulphate (1 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atropine alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (20 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.625 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoproterenol plus atropine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoproterenol or atropine pre-treatment
Number of subjects: 15
Study: 31585191

Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (low-dose: 102; mid-dose: 101; high-dose: 101)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo (102 initial; 181 booster)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (all doses)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (mid-dose and high-dose)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (low-dose and placebo)
Number of subjects: 404
Study: 28842581

Group type: EXPERIMENTAL
Intervention: C34-PEG4-Chol (10 mg, 10 mg, and 20 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: C34-PEG4-Chol (10 mg, 20 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 25757714

Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT for psychosis (CaCBTp) plus treatment as usual (TAU)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 116
Study: 22874661

Group type: EXPERIMENTAL
Intervention: Physical exercise (3 weekly sessions for 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (1 weekly session for 12 weeks)
Number of subjects: 36
Study: 21461372

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard supportive care)
Number of subjects: 0
Study: 19788025

Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg daily for 15 days
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 17390549

Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14967267

Group type: EXPERIMENTAL
Intervention: Single‐piece AcrySof IOLs (AcrySof SA30 or SA60)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Multipiece AcrySof IOLs (AcrySof MA30 or MA60)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 52
Study: 11676093

Group type: EXPERIMENTAL
Intervention: Handbills as a medium for public relations for the Nutrition Seminar.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local voluntary organization route for distributing handbills.
Number of subjects: 0
Study: 9360254

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ofloxacin (400 mg)
Number of subjects: 20
Study: 8508863

Group type: EXPERIMENTAL
Intervention: 15 mg zofenopril once daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3327854

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Flordipine 25 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Flordipine 50 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31279794

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone and 10 mg yohimbine combined
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 27785892

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IL-2
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 312
Study: 25956282

Group type: EXPERIMENTAL
Intervention: Interactive voice response phone call followed by a letter 1 week later if primary non-adherence continued
Number of subjects: 245

Group type: COMPARATOR
Intervention: No outreach (control group)
Number of subjects: 245
Study: 24020152

Group type: EXPERIMENTAL
Intervention: Visual cue
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Auditory cue
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined audio-visual cue
Number of subjects: 69

Group type: COMPARATOR
Intervention: No cue
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Smart grab bars with cues
Number of subjects: 69
Study: 22123383

Group type: EXPERIMENTAL
Intervention: icatibant
Number of subjects: 88

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study: 19550428

Group type: EXPERIMENTAL
Intervention: Two cups of decaffeinated Italian espresso coffee
Number of subjects: 15

Group type: COMPARATOR
Intervention: One cup of decaffeinated Italian espresso coffee
Number of subjects: 15
Study: 17362456

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine-soaked sponge (Group R, n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2% lidocaine-soaked sponge (Group L, n = 32)
Number of subjects: 64
Study: 15465617

Group type: EXPERIMENTAL
Intervention: Lower dose of pegylated interferon weekly alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 0
Study: 11806858

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (induced by reducing plasma tryptophan by 80%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (plasma tryptophan reduced by 16%)
Number of subjects: 30
Study: 9495509

Group type: EXPERIMENTAL
Intervention: Calcium (1600 mg/day as the citrate)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 7992293

Group type: EXPERIMENTAL
Intervention: Lovastatin (20, 40 and 80 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pravastatin (10, 20 and 40 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lovastatin and Pravastatin
Number of subjects: 48
Study: 2522392

Group type: EXPERIMENTAL
Intervention: Integrated/social interaction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Integrated/child-directed
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Segregated/social interaction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Segregated/child-directed
Number of subjects: 56
Study: 1227823

Group type: EXPERIMENTAL
Intervention: Betahistidine hydrochloride, 4 mg three times daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double blind study with Betahistidine hydrochloride
Number of subjects: 50
Study: 29894705

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both tDCS and Escitalopram
Number of subjects: 236
Study: 28700009

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single-port laparoscopic cholecystectomy
Number of subjects: 40
Study: 25636234

Group type: EXPERIMENTAL
Intervention: Viewing fruit and vegetable advertisements (prime condition)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Control condition (no advertisements)
Number of subjects: 907
Study: 23174515

Group type: EXPERIMENTAL
Intervention: OPUS (intensive early-intervention programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPUS
Number of subjects: 0
Study: 21714689

Group type: EXPERIMENTAL
Intervention: Collaborative depression care intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual depression care
Number of subjects: 249
Study: 18492265

Group type: EXPERIMENTAL
Intervention: NP 06‐1 (370 mg each, two capsules twice daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NP 06‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16980638

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Pain intensity increase between 6 and 12 months
Number of subjects: 270
Study: 14585550

Group type: EXPERIMENTAL
Intervention: Standard opioid management plus Reiki (Arm B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard opioid management plus rest (Arm A)
Number of subjects: 24
Study: 11085972

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study: 8614967

Group type: EXPERIMENTAL
Intervention: 600 IU of rHuEPO per kg of body weight intravenously twice a week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1393034

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of up to 20 mg papaveretum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 2862523

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Evening-primrose oil
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Injection of lignocaine and hydrocortisone
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Progestagens
Number of subjects: 291
Study: 29679427

Group type: EXPERIMENTAL
Intervention: 1-IOD
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2-IOD
Number of subjects: 21
Study: 29433845

Group type: EXPERIMENTAL
Intervention: Instructor-led HBA program for 6 months, followed by DVD-guided HBA for another 6 months
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 232
Study: 26963505

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (25 mg), inserted 4-weekly for 12 weeks
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo ring, inserted 4-weekly for 12 weeks
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (25 mg)
Number of subjects: 280
Study: 24507870

Group type: EXPERIMENTAL
Intervention: SMFV (white rice with protein-rich main dishes, fat-rich food item, and vegetables)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SMF (white rice with protein-rich main dishes and fat-rich food item)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SM (white rice with protein-rich main dishes)
Number of subjects: 9

Group type: COMPARATOR
Intervention: S (white rice alone)
Number of subjects: 9
Study: 23225837

Group type: EXPERIMENTAL
Intervention: Fluorometholone combined with pranoprofen eye drops
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fluorometholone eye drops
Number of subjects: 27
Study: 21029467

Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention (12-month multi-component school-based intervention including enhanced school sport sessions, interactive seminars, nutrition workshops, lunch-time physical activity sessions, PA and nutrition handbooks, parent newsletters, pedometers for self-monitoring, text messaging for social support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention
Number of subjects: 0
Study: 16930863

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 106